AR100975A1 - Inhibidores de fosfatidilinositol 3-quinasa - Google Patents

Inhibidores de fosfatidilinositol 3-quinasa

Info

Publication number
AR100975A1
AR100975A1 ARP150102013A ARP150102013A AR100975A1 AR 100975 A1 AR100975 A1 AR 100975A1 AR P150102013 A ARP150102013 A AR P150102013A AR P150102013 A ARP150102013 A AR P150102013A AR 100975 A1 AR100975 A1 AR 100975A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkylene
alkyl
aryl
or1x
Prior art date
Application number
ARP150102013A
Other languages
English (en)
Inventor
Anne Treiberg Jennifer
L Stevens Kirk
J Purvis Ii Lafe
Phillips Gary
Perreault Stephane
Patel Leena
Naduthambi Devan
Kim Musong
Kaplan Joshua
Evarts Jerry
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR100975A1 publication Critical patent/AR100975A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Reivindicación 1: Un compuesto caracterizado porque tiene la estructura de la fórmula (1), A es N o CH; n es 0, 1, 2, 3, ó 4; m es 0, 1, 2, 3, ó 4; cada R¹ se selecciona independientemente de alquilo opcionalmente sustituido, haloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, halo, ciano, NHC(=O)alquileno-N(R¹ˣ)₂, NO₂, OR¹ˣ, N(R¹ˣ)₂, OC(=O)R¹ˣ, C(=O)R¹ˣ, C(=O)OR¹ˣ, aril-OR¹ʸ, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, NR¹ˣC(=O)alquileno-C(=O)OR¹ˣ, aril-O-alquileno-N(R¹ˣ)₂, aril-O-C(=O)R¹ˣ, alquileno-C(=O)OR¹ˣ, alquileno-C(=O)N(R¹ˣ)₂, alquileno-C(=O)-Het, O-alquileno-C(=O)OR¹ˣ, alquileno-O-alquileno-C(=O)OR¹ˣ, C(=O)NR¹ˣSO₂R¹ˣ, alquileno-N(R¹ˣ)₂, alquenileno-N(R¹ˣ)₂, C(=O)NR¹ˣ-alquileno-OR¹ˣ, C(=O)NR¹ˣ-alquileno-Het, O-alquileno-N(R¹ˣ)₂, O-alquileno-CH(OR¹ʸ)CH₂N(R¹ˣ)₂, O-alquileno-Het, O-alquileno-C(=O)OR¹ˣ, O-alquileno-C(=O)-Het, S-alquileno-OR¹ˣ, O-alquileno-OR¹ˣ, O-alquenileno C₁₋₆-CH(OR¹ʸ)alquenileno C₁₋₆-OR¹ˣ, O-alquileno-NR¹ˣC(=O)OR¹ˣ, NR¹ˣ-alquileno-N(R¹ˣ)₂, NR¹ˣC(=O)R¹ˣ, NR¹ˣC(=O)N(R¹ˣ)₂, N(SO₂-alquilo)₂, NR¹ˣ(SO₂-alquilo), SO₂R¹ᶻ, SO₂N(R¹ˣ)₂, alquileno-arilo, alquileno-Het, alquileno-OR¹ʸ, alquileno-N(R¹ˣ)₂, C(=O)N(R¹ˣ)₂, NHC(=O)alquileno-arilo, aril-O-alquileno-N(R¹ˣ)₂, aril-OC(=O)R¹ʸ, NHC(=O)alquileno-heterocicloalquilo, NHC(=O)alquileno-Het, O-alquileno-O-alquileno-C(=O)OR¹ʸ, C(=O)alquileno-Het, y NHC(=O)halo-alquilo, en donde Het es heteroarilo opcionalmente sustituido o heterocicloalquilo opcionalmente sustituido, en donde R¹ˣ es independientemente hidrógeno, alquilo opcionalmente sustituido, haloalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, y arilo opcionalmente sustituido, en donde Rʸ es independientemente hidrógeno, alquilo opcionalmente sustituido, haloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, y heteroarilo opcionalmente sustituido, y en donde R¹ᶻ es independientemente alquilo opcionalmente sustituido, haloalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, y arilo opcionalmente sustituido; cada R² se selecciona independientemente de halo, ciano, alquilo opcionalmente sustituido, haloalquilo, SO₂N(R²ˣ)₂, y alcoxi opcionalmente sustituido, en donde R²ˣ es hidrógeno, alquilo opcionalmente sustituido, o haloalquilo opcionalmente sustituido; R³ es hidrógeno, alquilo opcionalmente sustituido, haloalquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, o heterocicloalquilo opcionalmente sustituido; R⁵ es hidrógeno o alquilo, o R⁵ y R³ junto con los átomos a los cuales se unen opcionalmente forman un anillo heterocíclico de cuatro, cinco o seis miembros opcionalmente sustituido; R⁴ es ciano, C(=O)NR⁴ˣR⁴ʸ, SO₂-alquilo, halo, haloalquilo, o C(=O)R⁴ˣ, en donde cada R⁴ˣ y R⁴ʸ es independientemente hidrógeno, alquilo opcionalmente sustituido, y haloalquilo opcionalmente sustituido; R⁶ es NH₂, halo, alquilo opcionalmente sustituido, o haloalquilo opcionalmente sustituido; y R⁷ es NH₂, halo, alquilo opcionalmente sustituido, o haloalquilo opcionalmente sustituido; con la condición de que cuando R⁵ y R³ forman un anillo heterocíclico de 5 miembros que se sustituye opcionalmente con hidroxilo, halo, o metoxi, R⁴ es ciano, R⁶ es amino, y R⁷ es amino; o una sal farmacéuticamente aceptable, isómero, o una mezcla de los mismos.
ARP150102013A 2014-06-24 2015-06-23 Inhibidores de fosfatidilinositol 3-quinasa AR100975A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462016194P 2014-06-24 2014-06-24

Publications (1)

Publication Number Publication Date
AR100975A1 true AR100975A1 (es) 2016-11-16

Family

ID=53674285

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102013A AR100975A1 (es) 2014-06-24 2015-06-23 Inhibidores de fosfatidilinositol 3-quinasa

Country Status (19)

Country Link
US (2) US9765060B2 (es)
EP (1) EP3160960B1 (es)
JP (2) JP6391718B2 (es)
KR (1) KR20170015521A (es)
CN (1) CN106459008A (es)
AR (1) AR100975A1 (es)
AU (1) AU2015280138B2 (es)
BR (1) BR112016029846A2 (es)
CA (1) CA2953820A1 (es)
EA (1) EA201692487A1 (es)
ES (1) ES2900812T3 (es)
HK (1) HK1231474A1 (es)
IL (1) IL249404A0 (es)
MA (1) MA40045A (es)
MX (1) MX2016017110A (es)
NZ (1) NZ727185A (es)
SG (1) SG11201610341PA (es)
TW (1) TW201625558A (es)
WO (1) WO2015200352A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952012A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
KR20170010063A (ko) 2014-06-13 2017-01-25 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
NZ726055A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
SG11201610095SA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
EP3164400A1 (en) 2014-07-04 2017-05-10 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) * 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
US10396145B2 (en) * 2017-01-12 2019-08-27 Micron Technology, Inc. Memory cells comprising ferroelectric material and including current leakage paths having different total resistances
US20200165257A1 (en) * 2017-06-22 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer
SG11202000523PA (en) * 2017-07-31 2020-02-27 The Trustees Of Columbia Univeristy In The City Of New York Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CA3114260A1 (en) * 2018-09-27 2020-04-02 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
CN110590681B (zh) * 2019-09-30 2021-06-01 中山大学 一种新型喹唑啉酮类化合物及其制备方法和应用
WO2021086966A1 (en) * 2019-10-29 2021-05-06 Biogen Ma Inc. Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
CN113512042A (zh) * 2020-04-09 2021-10-19 成都赜灵生物医药科技有限公司 取代喹唑啉-4-酮类化合物及其制备方法和用途
WO2024064024A1 (en) * 2022-09-19 2024-03-28 Onkure, Inc. ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DK1939203T3 (en) 2000-04-25 2015-02-23 Icos Corp INHIBITORS OF HUMAN phosphatidyl-inositol 3-kinase DELTA ISOFORM
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
SG10201605472WA (en) * 2008-01-04 2016-09-29 Intellikine Llc Certain Chemical Entities, Compositions And Methods
WO2011146882A1 (en) * 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
RU2014111823A (ru) * 2011-08-29 2015-10-10 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
WO2014100767A1 (en) * 2012-12-21 2014-06-26 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
WO2014128612A1 (en) * 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US20150148345A1 (en) * 2013-11-26 2015-05-28 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CA2952012A1 (en) * 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
KR20170010063A (ko) * 2014-06-13 2017-01-25 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제

Also Published As

Publication number Publication date
AU2015280138A1 (en) 2016-12-22
JP6391718B2 (ja) 2018-09-19
EP3160960A1 (en) 2017-05-03
US20180065953A1 (en) 2018-03-08
JP2017519021A (ja) 2017-07-13
AU2015280138B2 (en) 2018-06-14
NZ727185A (en) 2018-04-27
KR20170015521A (ko) 2017-02-08
JP2018090644A (ja) 2018-06-14
EP3160960B1 (en) 2021-10-13
WO2015200352A1 (en) 2015-12-30
US9765060B2 (en) 2017-09-19
IL249404A0 (en) 2017-02-28
MA40045A (fr) 2021-06-02
CA2953820A1 (en) 2015-12-30
US20160024054A1 (en) 2016-01-28
CN106459008A (zh) 2017-02-22
TW201625558A (zh) 2016-07-16
SG11201610341PA (en) 2017-01-27
ES2900812T3 (es) 2022-03-18
MX2016017110A (es) 2017-05-01
HK1231474A1 (zh) 2017-12-22
BR112016029846A2 (pt) 2017-08-22
EA201692487A1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100808A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR119454A2 (es) COMPUESTOS ÚTILES COMO MODULADORES DE RORg, SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, COMPOSICIONES FARMACÉUTICAS Y DICHOS COMPUESTOS PARA USO COMO MEDICAMENTO
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR114950A1 (es) Compuestos de benzamida
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR110922A1 (es) Compuestos inhibidores del vih
AR095464A1 (es) Compuestos de heteroarilo y usos de los mismos
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR097866A1 (es) Derivados de 4-azaindol
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR103742A1 (es) Derivados de trifluorometilpropanamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure